ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 10 Ô 24 ÈÕ£¬£¬£¬£¬£¬£¬NMPA ¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬ºãÈðÒ½Ò©µÄ 2.3 ÀàÐÂÒ©ºã¸ñÁо»Èð¸ñÁÐÍ¡¶þ¼×Ë«ëÒ»ºÊÍÆ¬£¨¢ñ£©¡¢ºã¸ñÁо»Èð¸ñÁÐÍ¡¶þ¼×Ë«ëÒ»ºÊÍÆ¬£¨¢ò£©»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬Ë³Ó¦Ö¢Îª£ºÅäºÏÒûʳ¿ØÖƺÍÔ˶¯£¬£¬£¬£¬£¬£¬ÓÃÓÚ¾¶þ¼×Ë«ëÒÖÎÁÆÑªÌÇ¿ØÖƲ»¼ÑµÄ³ÉÈË 2 ÐÍÌÇÄò²¡»¼Õß¡£¡£¡£¡£¡£¡£
2. 10ÔÂ24ÈÕ£¬£¬£¬£¬£¬£¬NMPA ¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬£¬ÉñÍþÒ©Òµ¼¯ÍÅ×ÔÖ÷Ñз¢µÄÉýÏÝÌÀ¿ÅÁ££¨¹úÒ©×¼×ÖC20250014£©Õýʽ»ñÅúÉÏÊС£¡£¡£¡£¡£¡£ÕâÊÇÉñÍþÒ©Òµ¼¯ÍŵÚËĸö¾µäÃû·½ÅúÎÄ£¬£¬£¬£¬£¬£¬Ò²ÊǺӱ±Ê¡ÄÚÊ׸ö»ñÅúµÄÉýÏÝÌÀ¿ÅÁ£ÖƼÁ¡£¡£¡£¡£¡£¡£
3. 10ÔÂ24ÈÕ£¬£¬£¬£¬£¬£¬µÂ¹úÖÆÒ©¾ÞÍ·°Ý¶ú£¨Bayer£©Ðû²¼£¬£¬£¬£¬£¬£¬ÆäÁ¢ÒìÒ©ÎïLynkuet£¨Í¨ÓÃÃû£ºelinzanetant£©Õýʽ»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©Åú×¼£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƾø¾Ïà¹ØµÄÖжÈÖÁÖØ¶È³±ÈÈ£¨Ñª¹ÜÊæËõÖ¢×´£¬£¬£¬£¬£¬£¬VMS£©¡£¡£¡£¡£¡£¡£
4. 10ÔÂ24ÈÕ£¬£¬£¬£¬£¬£¬Èð²©ÉúÎï¼°Æä×Ó¹«Ë¾Ribocure PharmaceuticalsÅäºÏÐû²¼Å·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©ÊÚÓèÆäС×ÌÈÅRNA£¨siRNA£©ºòѡҩÎïRBD1016¹Â¶ùÒ©×ʸñ£¨ODD£©£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƶ¡Ð͸ÎÑײ¡¶¾£¨HDV£©µÄѬȾ¡£¡£¡£¡£¡£¡£
1. 10ÔÂ26ÈÕ£¬£¬£¬£¬£¬£¬Åµ»ª¹«Ë¾Ðû²¼ÒѸ濢ÐÒéÒÔ120ÒÚÃÀÔªÊÕ¹ºAvidity Biosciences£¨Nasdaq:RNA£©£¬£¬£¬£¬£¬£¬ÕâÊÇÒ»¼Ò×ܲ¿Î»ÓÚÊ¥µüÑǸêµÄÉúÎïÖÆÒ©¹«Ë¾£¬£¬£¬£¬£¬£¬×¨×¢ÓÚÒ»ÖÖеÄÖÎÁÆÒªÁ죬£¬£¬£¬£¬£¬Äܹ»½«RNAÁÆ·¨µÝË͵½¼¡Èâ¡£¡£¡£¡£¡£¡£´Ë´ÎÊÕ¹º½«ÔÚAvidityÔçÆÚ¾«×¼ÐÄÔಡѧÏîÄ¿·Ö²ðΪSpinCoÖ®ºó¾ÙÐÐÖ®ºó¾ÙÐС£¡£¡£¡£¡£¡£SpinCoÔ¤¼Æ½«³ÉΪһ¼ÒÉÏÊй«Ë¾¡£¡£¡£¡£¡£¡£
1. 10ÔÂ22ÈÕ£¬£¬£¬£¬£¬£¬Gladstone Ñо¿Ëù²©Ê¿ºó Li Feiya ×÷ΪÅäºÏµÚÒ»×÷Õߣ¬£¬£¬£¬£¬£¬ÔÚ¹ú¼Ê¶¥¼âѧÊõÆÚ¿¯ Nature ÉϽÒÏþÁËÌâΪ£ºMyocardial reprogramming by HMGN1 underlies heart defects in trisomy 21 µÄÑо¿ÂÛÎÄ¡£¡£¡£¡£¡£¡£¸ÃÑо¿·¢Ã÷£¬£¬£¬£¬£¬£¬Î»ÓÚ 21 ºÅȾɫÌåÉ쵀 HMGN1 »ùÒòµÄ¿½±´ÊýÔöÌí£¬£¬£¬£¬£¬£¬½éµ¼ÁËÐļ¡Ï¸°ûÖØ±à³Ì£¬£¬£¬£¬£¬£¬½ø¶øµ¼ÖÂÁËÌÆÊÏ×ÛºÏÕ÷£¨21 ÈýÌå×ÛºÏÕ÷£©»¼ÕßµÄÏÈÌìÐÔÐÄÔàȱÏÝ¡£¡£¡£¡£¡£¡£
[1]Ranade, S.S., Li, F., Whalen, S. et al. Myocardial reprogramming by HMGN1 underlies heart defects in trisomy 21. Nature (2025). https://doi.org/10.1038/s41586-025-09593-9
Ïà¹ØÐÂÎÅ